- Conditions
- Pancreas Cancer, Gastrointestinal Adenocarcinoma
- Interventions
- ultrasound
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,309
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma
- Interventions
- Atebimetinib, GnP, mGnP
- Drug
- Lead sponsor
- Immuneering Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 47
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Duarte, California + 40 more
- Conditions
- Pancreatic Cancer, Adenocarcinoma, Pancreatic Neoplasms
- Interventions
- FOLFIRINOX, IPI-926
- Drug
- Lead sponsor
- Andrew Ko
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Madison, Wisconsin
- Conditions
- Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
- Interventions
- Binimetinib, Palbociclib, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Carcinoma, Neuroendocrine Tumors
- Interventions
- Cixutumumab, depot octreotide
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
- Interventions
- CDX-585
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more
- Conditions
- Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
- Interventions
- AGuIX, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 60
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Aurora, Colorado + 46 more
- Conditions
- Cancer of Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
- Interventions
- M7824, Gemcitabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, mitomycin C, rubitecan
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- San Ramon, California • Buffalo, New York
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
- Interventions
- Recombinant Interleukin-12
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pancreatic Cancer
- Interventions
- Pancreatic Surgery, Radiation therapy, Cisplatin, 5-FU, Alpha-interferon, Gemcitabine
- Procedure · Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- AVA6103
- Drug
- Lead sponsor
- Avacta Life Sciences Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Interventions
- AMG 479
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Boston, Massachusetts
- Conditions
- Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
- Interventions
- Ionizing radiation (IR) therapy, Ionizing radiation (IR)
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
- Interventions
- MORAb-066
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
- Interventions
- TC-510, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- TCR2 Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- dexamethasone, fluorouracil, brachytherapy, phosphorus P32, radiation therapy
- Drug · Radiation
- Lead sponsor
- Center for Molecular Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2007
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Garden City, New York
- Conditions
- Pancreatic Cancer
- Interventions
- HB-adMSCs
- Biological
- Lead sponsor
- Hope Biosciences LLC
- Industry
- Eligibility
- Male only
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Myc Inhibitor OMO-103
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Olaparib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas